1-7 of 7
Nicholas E. Murphy
Close
Sort by
Journal Articles

Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

Hang Quach, Masa Lasica, Michael Low, Peter Mollee, Hock Choong Lai, Nicole Wong Doo, Jay Hocking, Philip Campbell, Nicholas E. Murphy, M Hasib Sidiqi, David Routledge, Jessica Heenan, Noemi Horvath, Richard Eek, William E. P. Renwick, Douglas Stuart Lenton, Lauren J Child, Georgia McCaughan, Belinda E Butcher, Deepmala Mazumdar, Anna Kalff
Journal: Blood
Blood (2023) 142 (Supplement 1): 2023.
https://doi.org/10.1182/blood-2023-185169
Published: 2023
Journal Articles

Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma

Jessie Zhao, Tiffany T. Khong, Malgorzata Gorniak, Abir Khaled, Zac McDonald, John Reynolds, Daniel Wong, Nicholas Bingham, Anna M. Johnston, Olga Motorna, Nicholas E. Murphy, Hang Quach, Liqiang Yang, Andrew Spencer
Journal: Blood
Blood (2023) 142 (Supplement 1): 3328.
https://doi.org/10.1182/blood-2023-179742
Published: 2023
Journal Articles

Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study

Emma Verner, Amanda Johnston, Nalini Pati, Eliza Hawkes, Hui-Peng Lee, Tara Cochrane, Chan-Yoon Cheah, Robin J Filshie, Duncan Purtill, Hanlon Sia, Anoop Kumar Enjeti, Christina Brown, Nicholas E. Murphy, Jennifer Curnow, Kenneth Lee, Mannu Walia, Belinda Butcher, Judith Trotman
Journal: Blood
Blood (2021) 138 (Supplement 1): 304.
https://doi.org/10.1182/blood-2021-149019
Published: 2021
Journal Articles

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Slavisa Ninkovic, Nicholas E. Murphy, Hasib Sidiqi, Craig Thomas Wallington-Beddoe, Anish Puliyayil, Costas K. Yannakou, Wojt Janowski, Flora Yuen, Andrew Spencer, Hang Quach
Journal: Blood
Blood (2021) 138 (Supplement 1): 1671.
https://doi.org/10.1182/blood-2021-151871
Published: 2021
Journal Articles

Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Khai Li Chai, Cameron Wellard, Elizabeth M. Moore, Bradley Augustson, Akshay Bapat, Hilary Anne Blacklock, Rachel Elizabeth Cooke, Cecily Forsyth, Nada Hamad, Simon J Harrison, Phoebe Joy Ho, Jay Hocking, Ian H. Kerridge, Tracy King, Georgia J McCaughan, Peter Mollee, Orla Morrissey, Nicholas E. Murphy, Hang Quach, Xuan Ni Tan, Kimberly Wong, Andrew Spencer, Erica M. Wood, Zoe McQuilten
Journal: Blood
Blood (2021) 138 (Supplement 1): 4757.
https://doi.org/10.1182/blood-2021-147622
Published: 2021
Journal Articles

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Amanda Johnston, FRACP,FRCPA,MBBS,BMBS,MD, Nalini Pati, MBBS,FRACP,FRCPA, DCH, MD DNB, Eliza A Hawkes, Hui-Peng Lee, MBChB, FRACP, FRCPA, BHB, Tara Cochrane, MBBS,FRCPA,FRACP, Chan Y. Cheah, Duncan Purtill, MBBS,FRCPA,FRACP, Anoop K Enjeti, MBBS,FRCPA, FRACP,PhDMD,MRCP, Christina Brown, PhDFRACP,FRCPA,MBBS, Nicholas E. Murphy, FRCPA,MBBS,FRACP, Jennifer Curnow, MBBS, FRACP, FRCPA, PhD, Julia Carlson, Belinda Butcher, BSci, MBiostat, PhD, Judith Trotman, MBChB, FRACP, FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 4094.
https://doi.org/10.1182/blood-2019-124621
Published: 2019
Journal Articles

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Jane A. Freeman, BA, FRACP, FRCPA, MBBS, MPhil, MSc, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Richard Eek, MBCHB, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Nicholas E. Murphy, FRCPA, MBBS, FRACP, Duncan P. Carradice, MBBS, FRCPA, FRACP, Ann C. Solterbeck, BSc(hons) MSc PhDAStat, Oliver Giles Best, PhD BSc, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP
Journal: Blood
Blood (2018) 132 (Supplement 1): 3144.
https://doi.org/10.1182/blood-2018-99-116287
Published: 2018